Back to all trials
Nationwide Children's Hospital' Infant Corticosteroid Clinical Trial for Duchenne muscular dystrophy
Actively RecruitingPhase 4Reducing Inflammation
Study Overview
- Age
- 0–3 years
- Phase
- Phase 4
- Sponsor
- Nationwide Children's Hospital
- Therapeutic Approach
- Reducing Inflammation
- Variant Requirement
- Established clinical diagnosis of DMD and documented dystrophin gene mutation predictive of DMD phenotype.
- Eligible Sex
- Male
- Ambulation
- Ambulatory
- Study Start (Actual)
- 2021-04-30
- Primary Completion (Estimated)
- 2026-08
- Study Completion (Estimated)
- 2026-12
- Enrollment (Estimated)
- 26
- Countries
- United States
Study Requirements and Criteria
Steroid Use
Not yet provided
Inclusion Criteria
- Subjects ages 1 month through 30 months
- Weakness consistent with Duchenne on exam, creatine kinase ≥ 20 times the upper limit of normal, and genetic mutation known to be causative for DMD.
Exclusion Criteria
Prior treatment with Glucocorticosteroids
Contacts and Locations
Contacts and Locations
Contact
- Name: Sara Marshall
- Phone Number: 614-355-3508
- Email: [email protected]
Locations
This study has 4 locations
United States
Illinois Locations
Chicago, Illinois, United States, 60611
Actively Recruiting
Lurie Children's Hospital of Chicago
Ohio Locations
Cincinnati, Ohio, United States, 45220
Actively Recruiting
University of Cincinnati
Columbus, Ohio, United States, 43205
Actively Recruiting
Nationwide Children's Hospital
Contact: Kevin Warf, BS
Contact Mail: [email protected]
Contact Phone: (614) 355-2765
Texas Locations
Dallas, Texas, United States, 75235
Actively Recruiting
University of Texas Southwestern
Contact: Shahera Ranjha, MS
Contact Mail: [email protected]
Contact Phone: 214-456-5959
Clinical Trial Registry
NCT ID
NCT05412394This information is provided for educational purposes only. Always consult the study investigators before making medical decisions.